Home » Health » HAS does not recommend Valneva’s Covid-19 vaccine

HAS does not recommend Valneva’s Covid-19 vaccine

The organism of public health France’s Haute Autorité de Santé (HAS) has advised the government not to use the vaccine against COVID-19 biotechnological Valneva as part of its strategy for widespread vaccination.

As valid options point to injections of Sanofi yes GSK extensionVidPrevtyn Beta and that of Novavaxunder the name, Nuvaxovidto increase vaccination of people who cannot receive bivalent mRNA vaccines.

Specifically, the value of Valneva’s shares fell by 2.8% after the announcement of HAS

Valneva has obtained regulatory approval in the European Union for its vaccine against COVID-19 of the first generation, although it has recently been forced reduce financial forecasts yes cut jobs of work given the poor response it received. In the economic section, the company was greatly influenced by the recommendation of the French authorities, in particular the value of its shares decreased 2.8% after the announcement.

Valneva’s last months have been marked by a negative trend, in August the European Commission reduced the order for the vaccine to only 1.25 million doses of the 60 million expected previously. This news made him change his turnover forecast for this year between 340 and 360 million euros, some figures well below from its previous forecast which was between 430 and 590 million.

Because the health we all need… ConSalud.es

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.